Cayla N. Holmes, PA-C

Cayla Holmes practices at Healthtexas Provider Network in Dallas, Texas.

Cayla Holmes' NPI, 1134698939, was assigned on November 21, 2018.

Cayla Holmes' primary practice is Healthtexas Provider Network, at 301 N Washington Ave, Dallas, TX 75246 in Dallas County. The practice phone is (972) 712-3652.

Cayla Holmes' primary practice is Healthtexas Provider Network in Dallas, Texas. The medical group on file is HealthTexas Provider Network (HTPN). Dmand AI also links Cayla Holmes to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Cayla Holmes practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Cayla Holmes' primary specialty in the NPI Registry, under taxonomy code 363A00000X.

Dmand AI lists acute skin infection, benign or precancerous skin growths, contact dermatitis, hives, itchy rashes, minor injury to a limb, muscle pain, fibromyalgia, and limb pain and skin cyst among the conditions Cayla Holmes treats.

CMS data shows 721 Medicare services from Cayla Holmes across 10 procedure codes in 2024, for 235 Medicare patients. Medicare paid $31,451 for them. Every service was in an office.

CMS counts 235 Medicare patients who saw Cayla Holmes in 2024. The largest group is 65 to 74, with 129 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Cayla Holmes' median patient age at 39, with 74% women.

In 2024, Cayla Holmes wrote 137 Medicare Part D claims for 79 patients. 89% of them were for generic drugs. CMS names the drug for 76 of them, across 4 drugs with 11 or more claims each, at $3,628 in total drug cost.

Cayla Holmes accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 51 general payments to Cayla Holmes from 17 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 94% of the total. Abbvie Inc. paid the most, $377.